Turkish Professor Esma Yolcu Discovers a New Immunotherapy Molecule with Potential to Prevent Cancer Development
The recombinant protein SA-4-1BBL, an immune checkpoint activator discovered by Turkish scientist Esma Yolcu and her team, increases T cells’ anticancer effects. The molecule was also found to prevent other cancers from forming.

The 10 hallmarks of cancer include learning to evade the immune system. Immune checkpoint inhibitors (suppressors) and activators are molecules responsible for immune system regulation. The 2018 Nobel Prize in Medicine also focused on immune checkpoint inhibitors, which offer effective treatment by enabling immune recognition of cancer. Such immunotherapy drugs have been approved by the FDA for many cancer types. Research on immune checkpoint activators has also increased recently. In this context, in February 2019, Cancer Research published a study discovering that the newly developed recombinant protein SA-4-1BBL, T cells’ anticancer effects were enhanced. The molecule also prevented other cancers from forming. Because SA-4-1BBL provides both T-cell activation and cancer protection, it is a first of its kind.
The study was conducted at Lousville University in the United States. Turkish Professor Esma Yolcu and her team discovered that the molecule developed for cancer immunotherapy also protected against other cancer types.
In Preclinical (Laboratory and Animal) Studies;
- The molecule SA-4-1BBL, in mouse cancer models, increased the effectiveness of cancer vaccines. It successfully activated fighter CD8+ T cells and the adaptive immune system.
- The most interesting result was that mice given this molecule, even when injected with cancer cells, did not develop cancer . This suggests that the molecule may have cancer-preventive properties.
- Researchers believe it activates immune surveillance. Activation of CD4+ cells and natural killer cells provides protection against cancer formation.
- The cancer immunoprevention effect lasted longer than 8 weeks.
What Does the Study Mean for Us?
- It is important to emphasize that this is a preclinical study. Only after human clinical trials demonstrate its safety and effectiveness can it be used clinically.
- Immune checkpoint activators are being tested in clinical trials for various cancers. None has yet received FDA approval. Their most important feature is producing an effective anticancer response by sending positive signals to T cells.
- One of the most important features of this molecule is its potential to prevent other cancers from developing.
- Researchers plan to test the molecule in people at high cancer risk or with precancerous tumors for its immunoprevention properties.
The image above shows SA-4-1BBL’s effect on immune cells. SA-4-1BBL (green) binds to an immune cell (red), activating the immune system.
We congratulate Professor Esma Yolcu on this discovery and wish her continued success.
Sources
A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells.
Cancer Research, February 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.